CREBBP
CREB-binding protein
As of the edition of 20 October 2026, CREBBP (CREB-binding protein, UniProt Q92793) has 3 drugs tested at it and 4 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q92793
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 144
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Blood and lymph; Hormones; Inherited and neonatal; Infections; Nervous system
- Registered trials of its drugs
- 27
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| PRI-724 | Active | Phase 2 | none listed |
| Veledimex | Stopped | Phase 2 | none listed |
| E-7386 | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Castle Creek Biosciences | Route A |
| Alaunos Therapeutics | Route A |
The other 2 companies at CREBBP
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at CREBBP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.